Published in Psychopharmacology (Berl) on March 07, 2006
The neurobiology of psychopathic traits in youths. Nat Rev Neurosci (2013) 1.67
Measuring endogenous 5-HT release by emission tomography: promises and pitfalls. J Cereb Blood Flow Metab (2010) 1.16
Beneficial effects of desipramine on cognitive function of chronically stressed rats are mediated by alpha1-adrenergic receptors in medial prefrontal cortex. Prog Neuropsychopharmacol Biol Psychiatry (2010) 0.99
Inhibition of 5-HT neuron activity and induction of depressive-like behavior by high-frequency stimulation of the subthalamic nucleus. Proc Natl Acad Sci U S A (2007) 0.97
A new strategy for antidepressant prescription. Front Neurosci (2010) 0.96
The cannabinergic system is implicated in the upregulation of central NGF protein by psychotropic drugs. Psychopharmacology (Berl) (2010) 0.87
Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl) (2009) 0.87
Long-term administration of citalopram reduces basal and stress-induced extracellular noradrenaline levels in rat brain. Psychopharmacology (Berl) (2007) 0.86
Serotonin-2C and -2a receptor co-expression on cells in the rat medial prefrontal cortex. Neuroscience (2015) 0.84
Drug-drug conditioning between citalopram and haloperidol or olanzapine in a conditioned avoidance response model: implications for polypharmacy in schizophrenia. Behav Pharmacol (2012) 0.84
Subchronic treatment with fluoxetine and ketanserin increases hippocampal brain-derived neurotrophic factor, β-catenin and antidepressant-like effects. Br J Pharmacol (2012) 0.83
Fluvoxamine enhances prefrontal dopaminergic neurotransmission in adrenalectomized/castrated mice via both 5-HT reuptake inhibition and σ(1) receptor activation. Psychopharmacology (Berl) (2011) 0.82
5-HT₂A receptor inactivation potentiates the acute antidepressant-like activity of escitalopram: involvement of the noradrenergic system. Exp Brain Res (2013) 0.79
Adjunctive aripiprazole therapy with escitalopram in patients with co-morbid major depressive disorder and alcohol dependence: clinical and neuroimaging evidence. J Psychopharmacol (2013) 0.79
Involvement of serotonin 5-HT3 receptors in the modulation of noradrenergic transmission by serotonin reuptake inhibitors: a microdialysis study in rat brain. Psychopharmacology (Berl) (2013) 0.78
Molecular mechanisms underlying synergistic effects of SSRI-antipsychotic augmentation in treatment of negative symptoms in schizophrenia. J Neural Transm (Vienna) (2009) 0.76
Depression: perspectives from affective neuroscience. Annu Rev Psychol (2002) 3.72
Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry (2003) 3.14
Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) (1996) 2.91
Depression: a case of neuronal life and death? Biol Psychiatry (2004) 2.45
Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am (1996) 2.37
Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2003) 2.14
The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull (1999) 2.10
Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry (2001) 2.05
A novel augmentation strategy for treating resistant major depression. Am J Psychiatry (2001) 2.05
Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci (2000) 2.04
Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol (1999) 1.56
Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochem (1990) 1.51
Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl) (2002) 1.46
5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem (2001) 1.43
Are atypical antipsychotic drugs also atypical antidepressants? Aust N Z J Psychiatry (2001) 1.40
Central monoamines and their role in major depression. Prog Neuropsychopharmacol Biol Psychiatry (2004) 1.32
Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. J Pharmacol Exp Ther (1997) 1.29
Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry (1999) 1.22
Treatment algorithms in treatment-resistant depression. Psychiatr Clin North Am (1996) 1.16
Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology (2000) 1.14
A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence. J Clin Psychiatry (1990) 1.12
Augmentation and combination strategies in treatment-resistant depression. J Clin Psychiatry (2001) 1.07
Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential? Psychopharmacology (Berl) (1994) 1.06
S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J Pharmacol Exp Ther (2001) 1.05
R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: an in vivo microdialysis and receptor binding study. Neuropsychopharmacology (2002) 1.05
Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res (2002) 1.04
What role do atypical antipsychotic drugs have in treatment-resistant depression? J Clin Psychiatry (2002) 1.03
The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. J Clin Psychiatry (2004) 0.99
Antidepressants. J Clin Psychiatry (1997) 0.98
Role of serotonin in depression. Ann N Y Acad Sci (1990) 0.97
Effect of 5-HT1A receptor antagonists on citalopram-induced increase in extracellular serotonin in the frontal cortex, striatum and dorsal hippocampus. Neuropharmacology (1997) 0.96
Evidence that extracellular concentrations of dopamine are regulated by noradrenergic neurons in the frontal cortex of rats. J Neurochem (1994) 0.96
Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. Science (1999) 0.93
R(+)-8-OH-DPAT, a serotonin(1A) receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum. J Pharmacol Exp Ther (1999) 0.92
Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology (Berl) (1998) 0.91
A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression. Biol Psychiatry (1999) 0.91
Measuring antidepressant prescribing practice in a health care system using administrative data: implications for quality measurement and improvement. Jt Comm J Qual Improv (2000) 0.91
DOI, a 5-HT2A/2C receptor agonist, attenuates clozapine-induced cortical dopamine release. Brain Res (2001) 0.91
Treatment options for refractory depression. J Clin Psychiatry (1999) 0.89
Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex. Naunyn Schmiedebergs Arch Pharmacol (2003) 0.88
New approaches to the treatment of depression. J Clin Psychiatry (1996) 0.88
In vivo biogenic amine efflux in medial prefrontal cortex with imipramine, fluoxetine, and fluvoxamine. Synapse (1994) 0.88
Serotonin-mediated increase in prefrontal cortex dopamine release: pharmacological characterization. J Pharmacol Exp Ther (1996) 0.87
Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. Eur J Pharmacol (1998) 0.87
Electrophysiological evidence for a functional interaction between 5-HT1A and 5-HT2A receptors in the rat medial prefrontal cortex: an iontophoretic study. Synapse (1994) 0.86
Influence of 5-HT1A receptors on central noradrenergic activity: microdialysis studies using (+/-)-MDL 73005EF and its enantiomers. Neuropharmacology (1999) 0.85
Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology (Berl) (1996) 0.84
Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat. Neuropharmacology (2004) 0.84
Effects of serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibition plus 5-HT(2A) receptor antagonism on the firing activity of norepinephrine neurons. J Pharmacol Exp Ther (2002) 0.84
Depression and antidepressant therapy: receptor dynamics. Prog Neuropsychopharmacol Biol Psychiatry (1990) 0.84
The use of antidepressants in novel combination therapies. J Clin Psychiatry (2003) 0.83
Treatment of major depression: is improvement enough? J Clin Psychiatry (1999) 0.83
Fluoxetine increases extracellular dopamine in the prefrontal cortex by a mechanism not dependent on serotonin: a comparison with citalopram. J Neurochem (1999) 0.80
Selective reduction by isolation rearing of 5-HT1A receptor-mediated dopamine release in vivo in the frontal cortex of mice. J Neurochem (2002) 0.80
Histamine regulates food intake through modulating noradrenaline release in the para-ventricular nucleus. Brain Res (1999) 0.79
Characterization of endogenous serotonin-mediated regulation of dopamine release in the rat prefrontal cortex. Eur J Pharmacol (1999) 0.79
An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy. J Clin Psychiatry (2002) 0.78
Risperidone dose-dependently increases extracellular concentrations of serotonin in the rat frontal cortex: role of alpha 2-adrenoceptor antagonism. Neuropsychopharmacology (1997) 0.78
Adding risperidone to selective serotonin reuptake inhibitor improves chronic depression. J Clin Psychopharmacol (1998) 0.78
Tranylcypromine plus risperidone for treatment-refractory major depression. J Clin Psychopharmacol (2000) 0.78
Effect of acute treatment with YM992 on extracellular norepinephrine levels in the rat frontal cortex. Eur J Pharmacol (2000) 0.78
Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine. Psychopharmacology (Berl) (2004) 0.77
Reboxetine modulates norepinephrine efflux in the frontal cortex of the freely moving rat: the involvement of alpha 2 and 5-HT1A receptors. Neurosci Lett (2003) 0.77
Perospirone, a novel atypical antipsychotic drug, potentiates fluoxetine-induced increases in dopamine levels via multireceptor actions in the rat medial prefrontal cortex. Neurosci Lett (2004) 0.77
Augmentation of milnacipran by risperidone in treatment for major depression. Int J Neuropsychopharmacol (2004) 0.76
Effect of acute treatment with YM992 on extracellular serotonin levels in the rat frontal cortex. Eur J Pharmacol (2000) 0.76
Effect of pindolol pretreatment on MK-212-induced plasma cortisol and prolactin responses in normal men. Biol Psychiatry (1995) 0.76
Economic impact of olanzapine plus fluoxetine combination therapy among patients treated for depression: a pilot study. Psychopharmacol Bull (2003) 0.75
Biochemical profile of YM992, a novel selective serotonin reuptake inhibitor with 5-HT2A receptor antagonistic activity. Neuropharmacology (1996) 0.75
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry (2007) 5.64
A genome-wide investigation of SNPs and CNVs in schizophrenia. PLoS Genet (2009) 5.01
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry (2006) 4.12
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology (2003) 3.35
Feasibility, efficacy, and safety of antipsychotics for intensive care unit delirium: the MIND randomized, placebo-controlled trial. Crit Care Med (2010) 2.86
Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology (2006) 2.70
Macrophage metalloelastase mediates acute cigarette smoke-induced inflammation via tumor necrosis factor-alpha release. Am J Respir Crit Care Med (2003) 2.64
Cellular changes in the postmortem hippocampus in major depression. Biol Psychiatry (2004) 2.54
Alzheimer Disease: evaluation of a functional MR imaging index as a marker. Radiology (2002) 2.27
Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2003) 2.14
A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol (2005) 2.10
Tumor necrosis factor-alpha is central to acute cigarette smoke-induced inflammation and connective tissue breakdown. Am J Respir Crit Care Med (2002) 2.00
Role of ethnicity in antipsychotic-induced weight gain and tardive dyskinesia: genes or environment? Pharmacogenomics (2013) 1.97
Genetic variants in GPR126 are associated with adolescent idiopathic scoliosis. Nat Genet (2013) 1.90
Structure of protein phosphatase 2A core enzyme bound to tumor-inducing toxins. Cell (2006) 1.88
Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes (2002) 1.87
Common variants conferring risk of schizophrenia: a pathway analysis of GWAS data. Schizophr Res (2010) 1.79
Meta-analysis of genome-wide association studies confirms a susceptibility locus for knee osteoarthritis on chromosome 7q22. Ann Rheum Dis (2010) 1.75
Upregulation of cardiomyocyte ribonucleotide reductase increases intracellular 2 deoxy-ATP, contractility, and relaxation. J Mol Cell Cardiol (2011) 1.72
Cesarean delivery on maternal request in southeast China. Obstet Gynecol (2008) 1.68
Structural mechanism of demethylation and inactivation of protein phosphatase 2A. Cell (2008) 1.67
Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry (2007) 1.60
Neural responses to acute cocaine administration in the human brain detected by fMRI. Neuroimage (2005) 1.59
ACNP Task Force report on SSRIs and suicidal behavior in youth. Neuropsychopharmacology (2006) 1.49
Exome sequencing followed by large-scale genotyping suggests a limited role for moderately rare risk factors of strong effect in schizophrenia. Am J Hum Genet (2012) 1.47
Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response. Psychopharmacology (Berl) (2008) 1.46
Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev (2008) 1.46
Subunit-dependent modulation of septin assembly: budding yeast septin Shs1 promotes ring and gauze formation. J Cell Biol (2011) 1.40
Early life exposure to the 1959-1961 Chinese famine has long-term health consequences. J Nutr (2010) 1.40
High prevalence of hyperhomocysteinemia in Chinese adults is associated with low folate, vitamin B-12, and vitamin B-6 status. J Nutr (2007) 1.38
Conjoined twins: a worldwide collaborative epidemiological study of the International Clearinghouse for Birth Defects Surveillance and Research. Am J Med Genet C Semin Med Genet (2011) 1.37
A population-based case-control study of risk factors for neural tube defects in four high-prevalence areas of Shanxi province, China. Paediatr Perinat Epidemiol (2006) 1.33
Prepregnancy body mass index and gestational weight gain with the outcome of pregnancy: a 13-year study of 292,568 cases in China. Arch Gynecol Obstet (2012) 1.32
MTHFR 677C->T genotype is associated with folate and homocysteine concentrations in a large, population-based, double-blind trial of folic acid supplementation. Am J Clin Nutr (2011) 1.31
A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry (2005) 1.31
Gene expression profiling in postmortem prefrontal cortex of major depressive disorder. J Neurosci (2007) 1.30
Gastroschisis and associated defects: an international study. Am J Med Genet A (2007) 1.30
High-field magnetic resonance imaging of brain iron in Alzheimer disease. Top Magn Reson Imaging (2006) 1.29
Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl) (2009) 1.28
Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a consensus statement. J Clin Psychiatry (2010) 1.27
Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology (2007) 1.27
A mouse model for human osteogenesis imperfecta type VI. J Bone Miner Res (2013) 1.27
New sequence variants in HLA class II/III region associated with susceptibility to knee osteoarthritis identified by genome-wide association study. PLoS One (2010) 1.27
Maternal anaemia and preterm birth: a prospective cohort study. Int J Epidemiol (2009) 1.26
Suicide risk in schizophrenia: learning from the past to change the future. Ann Gen Psychiatry (2007) 1.25
Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. Schizophr Bull (2003) 1.24
Cohort profile: the International Childhood Cancer Cohort Consortium (I4C). Int J Epidemiol (2007) 1.24
Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology (2002) 1.23
Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation. Clin J Am Soc Nephrol (2008) 1.22
Gender-specific decrease in NUDR and 5-HT1A receptor proteins in the prefrontal cortex of subjects with major depressive disorder. Int J Neuropsychopharmacol (2008) 1.22
Extremely high prevalence of neural tube defects in a 4-county area in Shanxi Province, China. Birth Defects Res A Clin Mol Teratol (2006) 1.21
Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry (2012) 1.20
Multiple death pathways in TNF-treated fibroblasts: RIP3- and RIP1-dependent and independent routes. Cell Res (2011) 1.20
Spondylo-epiphyseal dysplasia, Maroteaux type (pseudo-Morquio syndrome type 2), and parastremmatic dysplasia are caused by TRPV4 mutations. Am J Med Genet A (2010) 1.20
Replication of the association of the aspartic acid repeat polymorphism in the asporin gene with knee-osteoarthritis susceptibility in Han Chinese. J Hum Genet (2006) 1.19
Geographical, seasonal and gender differences in folate status among Chinese adults. J Nutr (2003) 1.19
Structural and biochemical insights into the regulation of protein phosphatase 2A by small t antigen of SV40. Nat Struct Mol Biol (2007) 1.18
Dopamine D2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects. Biol Psychiatry (2009) 1.18
Large replication study and meta-analyses of DVWA as an osteoarthritis susceptibility locus in European and Asian populations. Hum Mol Genet (2009) 1.15
Adverse effects of dietary glycotoxins on wound healing in genetically diabetic mice. Diabetes (2003) 1.14
The structural basis for tight control of PP2A methylation and function by LCMT-1. Mol Cell (2011) 1.13
Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol (2004) 1.13
Awareness of disorder and suicide risk in the treatment of schizophrenia: results of the international suicide prevention trial. Am J Psychiatry (2004) 1.12
Transient relationships among BOLD, CBV, and CBF changes in rat brain as detected by functional MRI. Magn Reson Med (2002) 1.11
Characterization of effects of mean arterial blood pressure induced by cocaine and cocaine methiodide on BOLD signals in rat brain. Magn Reson Med (2003) 1.11
Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology (2006) 1.09
A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Clin J Am Soc Nephrol (2014) 1.08
Reduced glial and neuronal packing density in the orbitofrontal cortex in alcohol dependence and its relationship with suicide and duration of alcohol dependence. Alcohol Clin Exp Res (2006) 1.08
Radiofrequency power deposition utilizing thermal imaging. Magn Reson Med (2004) 1.08
Education-related gender differences in health in rural China. Am J Public Health (2004) 1.08
Pathway-based analysis of GWAS datasets: effective but caution required. Int J Neuropsychopharmacol (2010) 1.08
The impact of maternal anemia on perinatal mortality: a population-based, prospective cohort study in China. Ann Epidemiol (2009) 1.07
Cell therapy enhances function of remote non-infarcted myocardium. J Mol Cell Cardiol (2009) 1.07
Expectation modulates human brain responses to acute cocaine: a functional magnetic resonance imaging study. Biol Psychiatry (2007) 1.07
Lack of association between the CALM1 core promoter polymorphism (-16C/T) and susceptibility to knee osteoarthritis in a Chinese Han population. BMC Med Genet (2008) 1.07
Secular trends of macrosomia in southeast China, 1994-2005. BMC Public Health (2011) 1.07
Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology (Berl) (2003) 1.06
Hopelessness, neurocognitive function, and insight in schizophrenia: relationship to suicidal behavior. Schizophr Res (2003) 1.05
Formulation and in-vitro and in-vivo evaluation of a mucoadhesive gel containing freeze dried black raspberries: implications for oral cancer chemoprevention. Pharm Res (2007) 1.05
Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res (2002) 1.04
Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. Pharmacogenomics (2010) 1.04
WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity. J Pharmacol Exp Ther (2006) 1.03
The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions? Psychopharmacology (Berl) (2004) 1.03
A population-based birth defects surveillance system in the People's Republic of China. Paediatr Perinat Epidemiol (2003) 1.03
Structure and mechanism of the phosphotyrosyl phosphatase activator. Mol Cell (2006) 1.03
Differential trends in prevalence of diabetes and unrelated general medical illness for schizophrenia patients before and after the atypical antipsychotic era. Schizophr Res (2006) 1.03
Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol (2008) 1.02
Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms. Int J Neuropsychopharmacol (2004) 1.02
Association of rs11190870 near LBX1 with adolescent idiopathic scoliosis susceptibility in a Han Chinese population. Eur Spine J (2012) 1.01
Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology (2002) 1.00
CANT1 mutation is also responsible for Desbuquois dysplasia, type 2 and Kim variant. J Med Genet (2010) 0.99
Genetic variation of infant reduced folate carrier (A80G) and risk of orofacial defects and congenital heart defects in China. Ann Epidemiol (2005) 0.99
A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia. Neuropsychopharmacology (2010) 0.99
Lumbar disc degeneration is linked to a carbohydrate sulfotransferase 3 variant. J Clin Invest (2013) 0.98
Prevention and reversal of diabetic nephropathy in db/db mice treated with alagebrium (ALT-711). Am J Nephrol (2006) 0.98